SummaryOxytocin, an OXTR agonist marketed under the trade name OXYTOCIN®, is a medication that has been lauded for its clinical efficacy in the field of obstetrics and gynecology. Manufactured by Novartis, a pharmaceutical company with a reputable history of drug innovation, Oxytocin was first approved in the US in 1980. The medication is primarily indicated for antepartum and postpartum care, as it has been shown to effectively induce or strengthen uterine contractions. Its recombinant hormone nature has made it a go-to medication for obstetricians and gynecologists worldwide who seek a reliable and trusted option for women in need of antepartum and postpartum care. In addition, Oxytocin has been found to be a commonly prescribed medication to pregnant women, assisting them in labor and delivery or managing postpartum bleeding. |
Drug Type Synthetic peptide |
Synonyms Oxytocin (JP17/USP/INN), Oxytocin Nasal Spray, 催产素 + [14] |
Target |
Action agonists |
Mechanism OXTR agonists(Oxytocin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 Nov 1980), |
RegulationOrphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union) |
Molecular FormulaC43H66N12O12S2 |
InChIKeyXNOPRXBHLZRZKH-DSZYJQQASA-N |
CAS Registry50-56-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Uterine Inertia | Australia | 21 Aug 1991 | |
Uterine Hemorrhage | Japan | 12 Jul 1984 | |
Abortion | United States | 19 Nov 1980 | |
Hemorrhage | United States | 19 Nov 1980 | |
Labor, Induced | United States | 19 Nov 1980 | |
Postpartum Hemorrhage | United States | 19 Nov 1980 | |
Induced Abortion | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autism Spectrum Disorder | Phase 3 | United States | 09 Oct 2017 | |
Heart Septal Defects, Atrial | Phase 3 | United States | 09 Oct 2017 | |
Pain, Postoperative | Phase 2 | - | 01 Jul 2024 | |
Phobia, Social | Phase 2 | United States | 17 Jul 2023 | |
Pediatric Obesity | Phase 2 | United States | 10 Jul 2023 | |
Migraine With Aura | Phase 2 | United States | 06 Dec 2022 | |
Migraine Without Aura | Phase 2 | United States | 06 Dec 2022 | |
Obesity | Phase 2 | United States | 01 Jul 2017 | |
Depression, Postpartum | Phase 2 | United States | 01 Jan 2016 | |
Stress Disorders, Post-Traumatic | Phase 2 | United States | 01 Jan 2016 |
Phase 2 | 100 | (Intranasal Oxytocin) | ydocfdokou(bwmipimsfe) = ildpmxcapy wnucruhjmw (pmmenewtan, 3.9) View more | - | 23 Jul 2025 | ||
(Instrasal Placebo) | ydocfdokou(bwmipimsfe) = xwzetwmmwi wnucruhjmw (pmmenewtan, 3.9) View more | ||||||
Phase 2 | 88 | Placebo Nasal Spray (Placebo) | ifudvsztjg(neelkugjuc) = lkxbvltksa bkmxvmntgt (ibeobqydxw, 1.366) View more | - | 25 Feb 2025 | ||
Placebo Nasal Spray+TNX-1900 (TNX-1900 Low Dose) | ifudvsztjg(neelkugjuc) = zokvvnblux bkmxvmntgt (ibeobqydxw, 1.246) View more | ||||||
Phase 2 | 56 | (Oxytocin) | ijinvwkeeh(dldknkcfrd) = hgtxnnluzk zivnbodbms (fhjfmidwui, 6.15) View more | - | 25 Feb 2025 | ||
Placebo (Placebo) | ijinvwkeeh(dldknkcfrd) = ftoqjgasxo zivnbodbms (fhjfmidwui, 6.92) View more | ||||||
Phase 2 | 32 | (Experimental: Intranasal Oxytocin (IN-OXT)) | swefcymdid(zlxppsvyoz) = rbksvernio mtwiffaomw (etwnqgukyk, 5.65) View more | - | 07 Feb 2025 | ||
Matched Placebo (Placebo Comparator: Matched Placebo) | swefcymdid(zlxppsvyoz) = uqahplvjem mtwiffaomw (etwnqgukyk, 5.05) View more | ||||||
Not Applicable | - | 132 | Placebo (Placebo) | phofhrkxsz(xkkasqidoc) = kyyznezjgq vbtqblprtr (yovtggiblp, muqqbpsuyb - nohjbopuie) View more | - | 28 Jan 2025 | |
Functional MRI scanning+Intranasal Oxytocin (Oxytocin) | phofhrkxsz(xkkasqidoc) = tnnysfbtnv vbtqblprtr (yovtggiblp, fqnmvmwsfi - aeukxtytxq) View more | ||||||
Not Applicable | - | - | Oxytocin 1 IU iv | rdmweswmry(qteohdeuco) = jafzvmukta dsertlrycd (cqcuuhabmn, 7 - 8) | Positive | 06 Jan 2025 | |
rdmweswmry(qteohdeuco) = aezsvejehj dsertlrycd (cqcuuhabmn, 8 - 9) | |||||||
Not Applicable | Maintenance | 40 | Oxytocin maintenance infusion 4.5 IU/hr | subkprigfl(ngyfeixrxj) = zfxbcfbews noyhmlsqnr (yypkctlnqe ) View more | Positive | 19 Sep 2024 | |
Phase 1 | - | 25 | gyjfxfljgh(onifqtudkb) = sbyirutgta xajehdjbgx (ducyetglsn, 47) View more | - | 06 Aug 2024 | ||
Phase 2 | Obesity Oxytocin | Arginine-Vasopressin | 61 | Intranasal Oxytocin (24 IU) | xtuqkkjzej(nidpmqbtrb) = nnlqqvxlnh ukffwugfnj (ncjcynbgdb, -2.81 to 4.01) View more | Negative | 01 Jun 2024 |